Expert Roundtable: Exploring the Treatment Landscape of KRAS G12C-Mutated NSCLC

In part one of this roundtable discussion, Dr Melina Marmarelis, Dr Lova Sun, and Dr Hossein Borghaei, sat down with OLN to discuss KRAS G12C sensitive mutations in patients with lung cancer.

Expert Roundtable: Overcoming Resistance in KRAS G12C-Mutated NSCLC

In part two of this roundtable discussion, Dr Melina Marmarelis, Dr Lova Sun, and Dr Hossein Borghaei, sat down with OLN to discuss overcoming resistance to KRAS G12C sensitive mutations in...

Expert Roundtable: OS Rates Among Patients With EGFR Mutations in the TKI Era

In part one of this roundtable discussion moderated by Dr Edgardo Santos, a panel of experts sat down with Oncology Learning Network to discuss the rates of OS among patients with EGFR mutations...


Expert Roundtable: Biologic Differences Among EGFR/ERBB1 Mutations in Patients With Lung Cancer

In part two of this roundtable discussion, moderated by Dr Edgardo Santos, a panel of experts sat down with Oncology Learning Network to discuss the biological differences among EGFR/ERBB1 mutation

Expert Roundtable: The Management and Care of EGFR Patients

In part three of this virtual roundtable discussion, moderated by Dr Edgardo Santos, a panel of experts sat down with Oncology Learning Network to discuss the management and care of EGFR patients.<

Lung Cancer and Immunotherapy With Dr. Patrick Forde and Oswald Peterson

Dr Patrick Forde is joined by lung cancer veteran, Oswald Peterson, to discuss several recently approved immunotherapy options and how immunotherapy is advancing the treatment of lung cancer.

ZENITH20-4: Efficacy & Safety of Poziotinib in Treatment-Naïve NSCLC With HER2 Exon 20 Mutations

Dr Robin Cornelissen presents the results from the ZENITH20-4 study which evaluates the efficacy and safety of poziotinib in newly diagnosed patients with NSCLC and HER2 exon 20 insertion mutations.

Predicting Outcomes of Advanced NSCLC Patients Treated With PD-1/PDL

Dr Gilberto de Lima Lopes Jr discusses "Predicting Outcomes of Advanced NSCLC Patients Treated With PD-1/PDL."

Sotorasib For KRAS G12C-Mutated Lung Cancer

Dr Sarah B. Goldberg discusses sotorasib for KRAS G12C-Mutated lung cancer.

5-Year Survival Outcomes From The PACIFIC Trial

Dr David R. Spigel presents five-year survival outcomes from the PACIFIC trial, a placebo-controlled Phase III study of patients with unresectable stage III NSCLC who were treated with durvalumab.

Surgical Endpoints Are Needed in Lung Cancer Trials of Neoadjuvant Therapy

Dr Jonathan Spicer highlights the importance of introducing new endpoints in clinical trials of neoadjuvant approaches for lung cancer.

Lung Cancer Trial Updates at ASCO 2021

Dr Benjamin Besse discusses results from lung cancer trials that are anticipated in 2021.

WCLC 2020: Updates From the CHRYSALIS Trial And What it Means for Patients With NSCLC

In this expert discussion Dr Joshua Bauml and Dr Joshua Sabari speak about the updates from the CHRYSALIS trial and what it means for patients with NSCLC.

PIPSeN Trial: Olaparib Maintenance vs Placebo in Platinum-Sensitive NSCLC

Dr Sophie Postel-Vinay speaks about the PIPSeN trial, a randomized, double-blind phase II study that evaluated the PARPi olaparib as maintenance treatment in patients with platinum-sensitive advanced NSCLC.

Surgical Outcomes From the Phase III CheckMate 816 Trial

Dr Jonathan Spicer outlines surgical outcomes from CheckMate 816, a Phase III study evaluating nivolumab and platinum-doublet CT versus CT alone as neoadjuvant treatment for patients with resectable NSCLC.

Osimertinib + Ipilimumab in EGFR-Mutated NSCLC

Dr Sonam Puri discusses a trial which explores the combination of osimertinib, an EGFR TKI with ipilimumab, a monoclonal antibody drug in patients with EGFR mutant NSCLC as first line treatment.

Disease-Free Survival in IMpower010 Trial: Adjuvant Atezolizumab in NSCLC

Dr Sanjay Popat discusses results of the IMpower010 trial in patients with version 7 TNM, stage 1b resected non-small cell lung cancer.

Bispecific Antibodies in Lung Cancer

Dr Benjamin Besse outlines the role of bispecific antibodies in treating lung cancer.

IMpower010: Adjuvant Atezolizumab Improves DFS in Resected Stage II-IIIA NSCLC

Dr Heather Wakelee talks on the findings of IMpower010, a Phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA NSCLC.

Candid Conversations in Lung Cancer: Discussing Biomarker Testing and Targeted Therapies

PeerView has partnered with the LUNGevity foundation to bring the patient perspective into education directed to oncology and pathology professionals, and highlight the importance of having open conversations...

Checkpoint Inhibitors - Alone or With Chemotherapy in Lung Cancer?

Should patients with lung cancer with high PD-L1 expression be treated with checkpoint inhibitors alone or a combined checkpoint inhibitor and chemotherapy regimen? Dr Bruna Pellini highlights this as a major unanswered question in the field.

Evolving Applications of ctDNA in Lung Cancer: MRD, Early Detection, and Molecular Profiling

Dr Vamsidhar Velcheti outlines some of the evolving uses of ctDNA in lung cancer including molecular profiling, early disease detection, and relapse prediction.

Immunotherapy as a Game-Changer in Multimodal Management of Lung Cancer

Chair, Dr Brendon M. Stiles, Dr Boris Sepesi, and Dr Catherine Shu discuss immunotherapy advances in lung cancer in this presentation.

Lung Cancer Nursing UK Session at BTOG

Dr Catherine Henshall discusses the session on lung cancer nursing in the UK which took place at BTOG 2021.

No One Missed—NSCLC Biomarker Testing

Dr Jorge Gomez and Andrea Ferris discuss "No One Missed", a new campaign to raise awareness about comprehensive biomarker testing which can reveal vital information that can help identify the appropriate treatment...

Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

Dr Patrick Y. Wen discusses adjuvant osimertinib in resected EGFR-Mutated NSCLC.

Novel Therapies on the Horizon for Lung Cancer

Dr Samreen Ahmed discusses novel therapies for lung cancer such as those targeting KRAS mutations and antibody-drug conjugates for the treatment of HER2-driven non-small cell lung cancer.

Multisystem Immune-Related AEs With Immunotherapy in NSCLC

Jarushka Naidoo gives an overview of a study investigating immune-related adverse events associated with immune checkpoint inhibitor therapy for the treatment of NSCLC.

NERO Trial: PARP Inhibitors for Chemosensitive NSCLC

Dr Dean Fennell shares an update on the randomized Phase II/III NERO study investigating PARP inhibitors in patients with NSCLC who have previously responded to chemotherapy.

Antibiotics Impact Outcomes With Pembrolizumab in NSCLC Patients

Dr David Pinato outlines the impact of host determinants on response to immunotherapy in patients with NSCLC, highlighting PD-L1 expression as a biomarker for pembrolizumab response.

Guideline-Recommended Molecular Testing in Early-Stage NSCLC

This is a multidisciplinary look at molecular testing in early-stage non-small cell lung cancer.

Using Clinical Trials to Drive Treatment Approaches in Lung Cancer

Dr Andrew Robinson discusses the importance of using clinical trials to drive treatment approaches and summarizes the role of immunotherapies in the treatment of squamous NSCLC...

Systemic Treatment of Non-Oncogene Addicted NSCLC With Brain Metastases

Dr Lizza Hendriks discusses the systemic treatment of patients with non-small cell lung cancer and brain metastases who are non-oncogene addicted.


source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(235, 64, 52)